STAT

Opinion: On drug pricing, Trump could rely on bluster and bad ideas. But there’s a better alternative

In Trump's upcoming drug prices speech, will he regurgitate past sound bites or present constructive policy ideas?
Source: Pablo Martinez Monsivais/AP

As President Trump prepares to give a speech next week to address the issue of prescription drug prices, we wonder if we will witness the Trump of the presidential campaign, who slams the pharmaceutical industry for “getting away with murder” or a more measured, constructive Trump who recognizes the industry’s vital role in biomedical innovation and homes in on the role of payers and other middlemen?

The president, as we have all come to know, appears to devote far more attention to the politics of public policy than to the underlying policy itself. Indeed, he has tossed aside the script of formal speeches because the wonkish details offered by his aides were “a little boring.”

Although this is a disconcerting

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
Doctors Argue For Term Limits To Diversify Medical School Leadership
In a new paper, a group of doctors argues that medical schools should impose term limits on department chairs and deans to bring in more diverse perspectives.
STAT4 min readLeadership & Mentoring
Opinion: New Leaders Needed To Translate Discoveries Into Patient Care
To facilitate new discoveries, today's and tomorrow's leaders need to understand and navigate the languages and cultures of multiple sectors, from health care systems and academia to industry, finance, and…
STAT2 min readScience
New Vertex Cystic Fibrosis Drug Approved, Extending Treatments To 90% Of Patients
Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of therapy to 90% of CF patients. The drug will be marketed as Trikafta. The list price is $311,000 per year — the